cyrilzakka/clinical-trials huggingface dataset:
LSFG in Patients With Normal Tension Glaucoma Tension Glaucoma

Glaucoma is the second leading cause of blindness worldwide. Literature shows increasing evidence that dysfunction of ocular microcirculation in the optic nerve influences the progression of glaucoma. Laser speckle flowgraphy (LSFG) represents a non-invasive method to quantify ocular perfusion also at the ONH. LSFG enables noninvasive quantification of microcirculation of the optic disc in Japanese glaucoma patients


Eligibility Criteria:
Inclusion Criteria:

* Caucasian men and women aged over 50 years
* Subject is generally healthy with no current significant or a history of a significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, hematological or renal disorder, as determined by the investigator's clinical judgment through collection of medical history and performance of a physical examination. A significant disorder is defined as a disease or medical condition associated with impaired health status, requiring regular or current medical treatment and/or follow up. For the purposes of this study, an investigator may classify a medical condition as a nonsignificant disorder despite the fact that the subject receives treatment. Subjects having controlled Stage 1 hypertension (blood pressure of 140-159 mmHg systolic and/or 90-99 mmHg diastolic) are eligible for participation in this study
* Normal open angle in a gonioscopic examination
* Presence of glaucomatous optic disc changes in biomicroscopy and
* Visual field defects in at least two visual field examinations (Reliability criteria: fixation errors \< 20%, false positives \< 15%, and false negatives \< 33%) Or
* Abnormal circumpapillary retinal nerve fiber layer thinning (RNFL evaluated by OCT)

Exclusion Criteria:

* History of ocular or systemic disease causing optic nerve damage
* History of IOP greater than 21 mm Hg (corrected by CCT)
* Participation in a clinical trial in the 3 weeks preceding the study
* Ocular surgery (including intravitreal injection) during the 3 months preceding the study
* Ametropia \> 6 Dpt
* Smoking
* pre- or perimenopausal women
* Relevant ophthalmic diseases/conditions that could interfere with LSFG measurements (e.g. optic nerve head drusen, tilted disc, etc.)
* Opacities of the cornea (e.g. corneal scars, corneal oedema), the lens (e.g. LOCS-II grading \> 2, posterior capsule opacification) or the vitreous (e.g. vitreous haemorrhage, asteroid hyalosis)
* Patients who are not able to cooperate or with insufficient ability to fixate (tremor, nystagmus)
* Blood donation in the 3 weeks preceding the study
* Symptoms of a clinically relevant illness in the 3 weeks before the first study day
* Ocular infection or clinically significant inflammation
* Pregnancy, planned pregnancy or lactating
Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies

The application of positron emission tomography with lymphoproliferative diseases today provides diagnostic and therapeutic information of major importance , especially in terms of speed and quality of response to treatment. The radiopharmaceutical used in clinical practice for this exam is fluorodeoxyglucose 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (\[18F\]-FDG) . However , the uptake of this tracer is not elective in lymphoid tissues , with a lack of specificity. In addition , the avidity of this tracer is unequal according to the histological subtype (lack of sensitivity).

To try to improve the results of this clinical exploration of lymphoid malignancies, the investigators developed a new radiopharmaceutical ( \[18F\] - fludarabine ). The idea of transforming the fludarabine radiopharmaceutical is based on the existence of a fluorine atom in the molecule and the pharmacokinetic characteristics of this drug. The \[18F\]-Fludarabine is a new radiopharmaceutical reproducing the same dosage formulation of fludarabine , a drug used for the treatment of certain types of lymphoproliferative diseases, especially those where the tumor cells have a low proliferation kinetics . This drug is used in therapy in particular pharmacokinetic effect for a high affinity for the lymphoid tissue . Preclinical results on normal and lymphoma xenograft -bearing mice showed a specificity restricted to lymphoid tissue fixation with \[18F\]-Fludarabine compared with \[18F\]-FDG .

Based on these encouraging results , the investigators propose in this work to explore the Dosimetry and Biodistribution of \[18F\] - Fludarabine in human lymphoproliferative diseases : 1)A first group of patients with non-Hodgkin's large cell lymphomas in which it already has a wealth of experience in exploration \[18F\]-FDG, and 2) a second group of patients with chronic lymphocytic leukemia, where the results of the exploration \[18F\]-FDG are considered disappointing and did not, for this reason, experienced clinical development.


Eligibility Criteria:
Inclusion Criteria:

* Adult over 18
* Signed written informed consent
* Untreated stage B or C chronic lymphocytic leukemia
* Untreated diffuse large B-cell lymphoma
* Eligible for PET-CT
* The subject must be covered by a social security system

Exclusion Criteria:

* Age under 18
* Patients concurrently included in an investigational trial
* Weight over 120 kg
* pregnant women
* active infectious disease
* immune hemolytic anemia
* patients with creatinine clearance \< 30 ml/mn
* corticosteroid therapy
Yoga On Dyspnea, Sleep And Fatıgue In Chronıc Respıratory Dıseases

Although there are a limited number of studies in the literature investigating the effect of yoga on dyspnea, quality of life and respiratory functions of chronic respiratory patients There is no study examining the effect of yoga on sleep and fatigue of chronic respiratory patients. Therefore, this study was conducted to determine the effect of yoga on dyspnea, sleep, and fatigue applied to chronic respiratory patients.

Chronic respiratory diseases (CSFD) are chronic diseases of the airways and other structures of the lung. Two of the most common of these diseases are asthma and chronic obstructive pulmonary disease. Asthma and chronic obstructive pulmonary disease (COPD); mortality, morbidity and prevalence of chronic respiratory diseases are increasingly increasing across countries. COPD; It has been defined as a common, preventable and treatable disease characterized by permanent airflow restriction, which is associated with the increased chronic inflammatory response of the airways and lungs to harmful gases and particles Every year, 3 million people die of COPD in the world and this rate constitutes 6% of all deaths If it is asthma; It is defined as a heterogeneous disease characterized by chronic airway inflammation associated with airway hyperresponsiveness to direct or indirect stimuli. Asthma is seen at a rate of 1-18% in the whole world population

Eligibility Criteria:
Inclusion Criteria:

* Between the ages of 18-55 and diagnosed with asthma and COPD for at least six months,

  * Do not have any disease that causes insomnia and do not use sleeping pills
  * Has the ability to use the internet actively, download the ZOOM program to the phone or computer and participate in the application.

Have not participated in a similar regular exercise program in the last 6 months,

* Do not have any respiratory system disease other than asthma and COPDY,
* Not in exacerbation period,
* Do not have a physical illness or cognitive deficiency and a psychiatric disease that prevents understanding of the education given,
* Patients who were literate and volunteered to participate in the study were included in the study.

Exclusion Criteria:

* In the period of exacerbation Have participated in a similar regular exercise program in the last 6 months, Those who cannot download the ZOOM program and participate in the application
Oral Health Status and Diet History Analysis Among Orphan House Children From 10-14 Years in Cairo Governorate.

the purpose of study to determine oral health status and dietary habits among group of orphan children from 10-14 years in Cairo Governorate.

The study's investigators will record all data related to oral health status of orphan children from 10-14 years and their dietary habits to describe usual food intake and its variation over a long period of time . the OHI-S will also recorded which has 2 components the Debris index and Calculus index .

Eligibility Criteria:
Inclusion Criteria:

* Egyptian children aged from 10-14 years
* Cooperative children

Exclusion Criteria:

* Children with systemic disease , genetic disorders , or any disabilities
Association Between Dental Implants Properties and Malodor Production

Malodor production is bacterial in origin. The bacterial activity of anaerobic bacteria results in the breakdown of proteins and the production of foul smelling compounds. The aim of the study is to test the hypothesis that bacterial growth on dental implants contributes to malodor production and to see whether this contribution is associated with various properties of the dental implant such as: maker, type, depth ext.


Eligibility Criteria:
Inclusion Criteria:Dental patients that need dental implants -

Exclusion Criteria:smokers

-
89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.


Eligibility Criteria:
Inclusion Criteria:

* Patient age \> 25 years old and \< 80 years old
* Patients with reoccurrence of brain tumor
* The principal investigator or co-PI must review MRI and CT findings based on the radiologic assessment provided they meet the following imaging criteria (as established in the clinical trial 09-177):

OR

* Patients with newly diagnosed GBM and one of the following options:
* Eligible for surgery after the last research scan.
* Significant residual disease after initial surgery
* The principal investigator or co-PI must review MRI and CT findings and agree with the presence of significant residual disease
* Treatment (non-surgical) naïve
* Karnofsky Performance Score ≥ 70

Exclusion Criteria:

* Laboratory values:

  * Serum creatinine \>2.5 mg/dL.
  * AST (SGOT) \>2.5x ULN.
  * Bilirubin (total) \>1.5x ULN.
  * Serum calcium \>11 mg/dL.
* Pregnant or breastfeeding (if a female is of childbearing potential, and unsure of pregnancy status, a standard pregnancy test should be done).
* If an initial biopsy demonstrates neoplasm other than GBM
* Presence of any other co-existing condition which, in the judgment of the investigator, might increase the risk to the subject.
* Presence of serious systemic illness, including: uncontrolled inter-current infection, uncontrolled malignancy, significant renal disease, or psychiatric/social situations, which might limit compliance with study requirements
* Prior treatment.
* Other serious illness (es), which might preclude completion of this, study or interfere with determination of causality of any adverse effects experienced in this study.
Novel Real-world Methods in Social Drinkers and AUD

This research project proposes a novel approach to elucidate the biological adaptations associated with Alcohol Use Disorder and to assess whether such adaptations are predictive of higher alcohol craving in response to both alcohol cues and stressors and higher relapse risk and alcohol use in the real world.

We will use intensive longitudinal data collection and analysis across multiple data streams. We will recruit 25 treatment-seeking individuals with AUD and 25 light social drinkers matched on demographically relevant variables (i.e., age, gender, IQ, race). We will use smartphones to assess subjects' alcohol use and experiences in real-time via ecological momentary assessment (EMA). During three consecutive days of these two weeks, we propose using passive biomonitoring to collect real-time cardiovascular responses, i.e., heart rate variability (HRV), and alcohol use via unobtrusive monitors (i.e., Firstbeat Bodyguard 2, BACtrack Skyn) with scheduled salivary cortisol samples. Individuals with AUD will then be provided with four weeks of behavioral treatment with daily assessments. During the final two weeks of treatment, individuals with AUD will complete another three-day period of intensive self-reports, including another 72-hours physiological and salivary cortisol monitoring.

Eligibility Criteria:
Inclusion Criteria:

Men and women who:

1) Are older than 18 years old at the first intake appointment; 2) Are fluent in English; 3) Are drinking alcohol at levels to match either of the two groups:

a. Social drinkers: i. Must report a past-year history of alcohol use ii. Must not meet current AUD and may have only met mild AUD during their lifetime (not within the past year) iii. Provide a negative urine toxicology screen. b. Individuals with Alcohol Use Disorder: i. Must meet current criteria for AUD based on the SCID (≤ 2 symptoms in past year); ii. Report at least weekly use of alcohol. iii. Do not meet criteria for any other substance use disorders other than mild Cannabis Use Disorder.

iv. Provide a positive urine toxicology screen for alcohol during intake. 5) Can provide written informed consent.

Exclusion Criteria:

-
Quality of Life and Long-term Outcome of Adequately Treated Congenital Hypothyroidism

The primary objective of this observational study is the evaluation of the quality of life and long-term outccome of young-adult patients with congenital hypothyroidism diagnosed by neonatal screening receiving replacement treatment with levothyroxine.

The secondary objective is to relate the results to the form of hypothyroidism, the initial dose of L-T4, treatment adherence and genetics

The study protocol will be performed in 3 different phases:

Step1:

A) Enrollment of patients meeting the following criteria:

* diagnosis of congenital hypothyroidism through neonatal screening adequately treated with L-T4
* confirmation of the diagnosis of hypothyroidism upon re-evaluation of the diagnosis
* age 16-21 years at the time of enrollment

B) Information interview on the study and signing of informed consent by the patient and/or parent/guardian

C) Retrospective collection of the following parameters at diagnosis:

* Values of TSH, FT4 at diagnosis, initial dose of L-T4
* Thyroid ultrasound and scintigraphy reports
* Genetic investigation report if available

D) Retrospective collection for each year of follow-up of:

weight, height, TSH, FT4 and L-T4 dose

Step 2:

A) Clinical evaluation (Weight, Height, BMI, Waist and hip circumference, blood pressure) B) Evaluation of body composition by performing bioimpedance analysis C) Evaluation of quality of life through administration of the SF36 test D) Evaluation of cognitive abilities through administration of the WAIS IV test E) Evaluation of any psychopathological conditions through the SCL-90 psychopathological screening questionnaire F) For patients up to 18 years of age: CBCL questionnaire administered to parents to describe the patient's behaviour

Step 3:

Data collection and analysis of results

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of congenital hypothyroidism by neonatal screening
* Start of L-T4 therapy within the first month of life
* Confirmation of hypothyroidism condition upon reassessment of diagnosis

Exclusion Criteria:

* other chronic diseases and/or genetic syndromes
* family history of neuropsychiatric pathology
* familial dyslipidemia
Peri-procedural Smoking Cessation Program in Patients With Chronic Pain

This single arm study will assess whether smoking cessation counseling offered to chronic pain patients is effective in reducing pain and cigarette use.


Eligibility Criteria:
Inclusion Criteria:

* Chronic Pain of 3 months or greater
* Scheduled for interventional pain procedure

Exclusion Criteria:

* Cancer related pain
* Current participation in smoking abstinence program
* History of schizophrenia or other pyschotic disorder
* History of dementing illness
* Pregnant patients
* Diagnosis of depression or anxiety
To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions

To Demonstrate the Relative Bioequivalence of Lisinopril 1 x 40 mg Tablets Under Fasting Conditions.


Eligibility Criteria:
Inclusion Criteria:

* No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

* Positive test results for HIV or hepatitis B or C.
* Treatment for drug or alcohol dependence.
The MONARCH Case Series Study: SPRINT® Peripheral Nerve Stimulation for the Treatment of Head Pain

The purpose of this study is to learn if pain can be relieved by delivering small amounts of electricity (called "electrical stimulation") to the nerves at the top of the neck. This study will use a device called the SPRINT® PNS System. PNS stands for peripheral nerve stimulation (PNS). This device is cleared by the FDA for up to 60 days of use for relief of chronic or acute pain.


Eligibility Criteria:
Key Inclusion Criteria:

* Diagnosed cervicogenic headache (CGH) or occipital neuralgia (ON)

Key Exclusion Criteria:

* Prior cervical or cranial occipital surgery
* Implanted electronic device (dependent on implant's intended treatment, location, and electrical current pathway)
* Pregnant
The Significance of Release of T-follicular Helper and T-follicular Regulatory Cells in Autoimmune Haemolytic Anemia Before and After Tratment

we study the circulating T-follicular regulatory and T-follicular regulatory cells in autoimmune hemolytic anemia.

Autoimmune hemolytic anemia (AIHA) is an acquired autoimmune disease resulting in the production of antibodies directed against the patient's red blood cells (RBCs) causing shortened erythrocyte lifespan.

The main pathogensis of the disease is autoantibodies (Ab) that directed against erythrocytes, with or without complement (C) activation. The most common form of AIHA is warm AIHA characterized by the presence of warm-type autoantibodies-immunoglobulin G (IgG) which reacts optimally at 37 °C, causing RBC extravascular destruction by tissue macrophages .

Previous studies of the etiology and pathogenesis of AIHA have focused on the autoreactive B cells that have escaped tolerance mechanisms and regulatory T cells (Treg).

The main treatment of AIHA includes RBC transfusion and immune system inhibitors such as corticosteroids. During an immune response, CD4 Th cells can differentiate into several unique effector lineages that promote different immune responses via the secretion of distinct types of cytokines.

T follicular helper (Tfh) cells are a CD4 T cell lineage whose major function is to help B cells form germinal centers (GCs) and produce high-affinity antibodies(6). Tfh cells are characterized by expression of the CXCR5, the transcriptional repressor B cell lymphoma 6 (Bcl-6), programmed death 1 (PD-1), and inducible costimulator (ICOS).

Follicular regulatory T (Tfr) cells are a newly identified subset of Treg cells that coexpress markers of both Treg cells and Tfh cells. In addition to expressing Tfh-related markers, Tfr cells also express regulatory markers, such as FoxP3, CD25, CTLA-4, IL-10, and transforming growth factor β (TGFβ).

TFR cells represent a highly specialized subpopulation of Foxp3+ Tregs that co-express TFHfeatures, such as Bcl-6, CXCR5, ICOS, PD-1 and Treg features CD25 and Foxp3. TFR cells have the ability to inhibit TFH activation and cytokines production and suppress B cell GL7 and B7-1 expression and limited class switch recombination occurring in the GC via high expression of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and production of inhibitory cytokine- interleukin 10 (IL-10) and transforming growth factorβ (TGFβ)(5). The involvement of TFR cells in the pathogenesis of human autoimmune diseases remains speculative, but an alteration of the TFR:TFH ratio is observed in the blood of patients suffering from several autoimmune diseases, such as child immune thrombocytopenia, and rheumatoid arthritis.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed as autoimmune hemolytic anemia, primary or secondary, male or female, any age but not on treatment

Exclusion Criteria:

* Pregnancy or breast-feeding women
* Patients treated with corticoids or immunosuppressant.
* Patients with hematological malignance.
* Patients with alloimmune hemolytic anemia as ABO incompatibility or transplant patients
Mammography SPECT With Rotating Slant Hole Collimator

The goal is to conduct a pilot study to determine the feasibility of the clinical use of RMSSH SPECT imaging technology for breast imaging and to develop a standardized clinical protocol.

The goal of this protocol is to develop and evaluate a novel SPECT imaging technique for imaging the breast using rotating multi-segment slant-hole (RMSSH) collimators. The motivation is the requirement of a low cost RMSSH collimator and a conventional Large-Field-Of-View (LFOV) camera. It is believed that RMSSH SPECT is particularly suitable for applications in breast imaging.

Eligibility Criteria:
Inclusion Criteria:

* Women seen at Johns Hopkins Avon Division of Breast Imaging who have been diagnosed with breast cancer.

Exclusion Criteria:

* Pregnant (or possibly pregnant)
* Lactating
* Unable to give consent
* Weights over 300 pounds
* Women who have already undergone definitive surgical treatment to their breast for breast cancer will not be eligible.
Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer

This study is evaluating how well a music therapy program works to improve anxiety and stress in adolescents and young adults receiving cancer treatment.

This research study will test how well a music therapy program works to improve anxiety and stress in adolescents and young adults receiving cancer treatment. The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment.

Eligibility Criteria:
Inclusion Criteria:

* Age 15 - 39 years of age
* Have a diagnosis of any cancer
* Have begun treatment for cancer and plan to receive active cancer treatment (e.g., radiation, chemotherapy, or oral chemotherapy) over the next eight weeks
* Signed informed consent/assent
* Willingness to participate in all study activities
* Speak/read English

Exclusion Criteria:

* Prognosis \< 3 months,
* Self-report inability to physically interact with musical instruments (e.g., hold instruments)
* Documentation of significant hearing impairment (e.g., deaf).